The Rare Responsibility: Unauthorised Copies

Dear Impossible Readers,

Cancer is often characterised by uncontrolled growth, but ultra-rare cancers adhere to entirely different biological principles. Some are driven by a single fusion protein that modifies the epigenetic landscape, while others originate from immune precursors circulating in the bloodstream. Certain types excel by hijacking kinase signalling in otherwise healthy organs, whereas others survive within the protected environment of the brain. Rare cancers are not merely infrequent variants of common tumours. They are mechanistically distinct entities that challenge our understanding of how malignancy begins, progresses, and responds to treatment.

The range of rare cancers is striking. NUT Carcinoma (NC) results from a fusion that disrupts differentiation through epigenetic reprogramming, leading to an aggressive carcinoma. Alveolar Soft Part Sarcoma (ASPS), originating from mesenchymal tissue, features a fusion that promotes angiogenesis and early metastasis despite slow primary growth. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is not a solid tumour but a malignancy of innate immune precursors, often initially appearing in the skin before spreading systemically. Fibrolamellar Hepatocellular Carcinoma (FL-HCC) affects young people without liver disease and is driven by a kinase fusion protein. Primary Central Nervous System Lymphoma (PCNSL) occurs within the immune-privileged brain, where both biology and treatment are limited. These cancers demonstrate that rare cancers are a spectrum of distinct mechanisms, tissues, and challenges.

Treatment strategies reflect this biological diversity. Aggressive multimodal therapy, combining surgery, chemotherapy, and radiation, is often used for NC, but outcomes remain poor. ASPS responds poorly to standard chemotherapy but may respond to VEGF inhibitors, which block new blood vessel growth that is essential for tumour expansion. For BPDCN, CD123-targeted therapies like tagraxofusp, delivering a cytotoxin to malignant cells, have transformed treatment, signalling a move toward lineage-specific immunotherapy. Managed primarily by surgery when possible, FL-HCC benefits most from complete tumour removal, as systemic therapies often have limited success. PCNSL requires high-dose methotrexate (HD-MTX) to cross the blood–brain barrier and target CNS lymphoma cells, sometimes followed by autologous stem cell transplantation (ASCT), where a patient’s own stem cells are reinfused after intensive chemo to restore bone marrow. Across these diseases, precision medicine is vital, with understanding driver mutations or cellular origins guiding therapy.

Future treatments rely on more targeted biological approaches. BET inhibitors are small molecules that disrupt abnormal chromatin-binding proteins that sustain oncogenic transcription and are being studied for NC to reverse differentiation blockade. In ASPS, immune checkpoint inhibitors (ICIs), which counteract inhibitory signals on T cells to boost anti-tumour immunity, are under investigation given the tumour’s immunogenic nature. For BPDCN, chimeric antigen receptor T-cell therapy (CAR-T), where a patient’s T cells are engineered to target CD123-expressing cancer cells, shows promise as a future treatment. In FL-HCC, research centres on selective PKA pathway inhibitors to block continuous kinase signalling driven by the fusion protein. Additionally, new CNS-penetrant targeted therapies specifically designed to cross the blood–brain barrier, alongside combination immunomodulatory treatments, could transform PCNSL therapy. Rare cancers often act as models of clarity, as their dependence on a single fusion or pathway makes them highly suitable for precise targeted treatment.

Early molecular testing is essential for both patients and clinicians today. Rare cancers often go misdiagnosed or are mistaken for more common types, leading to treatment delays. Referring patients to specialised centres, enrolling them in rare cancer registries, and exploring clinical trials can significantly improve outcomes. Many ultra-rare cancers, such as NC, ASPS, BPDCN, FL-HCC, and PCNSL, have specific molecular drivers or biological contexts, making comprehensive genomic profiling urgent rather than optional. Despite their rarity, these cancers demand exceptional accuracy. Understanding their biological uniqueness is the crucial first step towards effective treatment.

Until the next rare post,
Yours Possibly

Which rare disease category would you like to see covered next?